Lemtrada (Alemtuzumab)

Alemtuzumab targets the CD52 antigen found on mature T and B lymphocytes. Binding to CD52 triggers antibody‑dependent cellular cytotoxicity and activates complement, leading to rapid destruction of these immune cells. The resulting lymphocyte depletion dampens the abnormal immune response that contributes to demyelination in multiple sclerosis.

The dosing regimen for Lemtrada is determined by the prescribing physician based on the approved label and individual patient factors. Typically, treatment involves two annual courses administered intravenously, but the exact dose, infusion rate, and schedule are set by the healthcare provider and should not be altered without medical guidance.

The safety of Lemtrada in pregnancy and lactation has not been established, and the product carries an unknown pregnancy category. It is generally advised to avoid use in pregnant or nursing women unless the potential benefits justify the potential risks, and decisions should be made in consultation with a qualified healthcare professional.

To request Lemtrada, submit an enquiry on the product page at gnhindia.com, specifying the required quantity. GNH India works with hospitals, pharmacies, and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details—including cold‑chain handling where required—and assistance with import documentation.

Lemtrada is a monoclonal antibody that depletes lymphocytes, whereas many other MS therapies are small‑molecule oral agents or interferon‑based injectables that modulate immune activity without profound cell depletion. This mechanism can offer efficacy in patients with highly active disease but also carries a distinct safety profile that requires careful monitoring.

Lemtrada must be stored refrigerated at 2 °C to 8 °C. It should be kept in its original packaging, protected from light, and must never be frozen or shaken. Prior to infusion, the solution is allowed to reach room temperature as directed by the prescribing information.

Lemtrada is given as an intravenous infusion in a clinical setting. The first course consists of daily infusions for five consecutive days, followed by a second course of three daily infusions one year later. Each infusion is administered under medical supervision with monitoring for infusion‑related reactions.

Serious risks include autoimmune disorders such as thyroid disease, immune thrombocytopenic purpura, and nephropathy, as well as severe infections and rare malignancies. Patients should be monitored regularly for signs of these conditions, and any new symptoms should be reported promptly to a healthcare professional.

Lemtrada is contraindicated in individuals with active infections, those who have received live vaccines within four weeks of treatment, and patients with known hypersensitivity to alemtuzumab or any component of the formulation. Caution is also advised for patients with a history of autoimmune disease or severe organ dysfunction.